National Institute on Drug Abuse; Notice of Closed Meetings, 11252-11253 [2011-4544]
Download as PDF
<![CDATA[
11252
Federal Register / Vol. 76, No. 40 / Tuesday, March 1, 2011 / Notices
who did not participate in the IFPS II.
All IFPS II participants who completed
at least two surveys after their infants
were born and for whom current contact
information can be found will be sent
the mailed questionnaire. This is
expected to be about 2,562 participants.
We estimate that 1,538 respondents will
return it and that it will take a
respondent 20 minutes (0.33 hours) to
complete the questionnaire, for a total of
513 hours. An additional 522 mothers
are expected to complete the telephone
interview of 20 minutes (0.33 hours) for
a total of 174 hours. An estimated 1,380
participants will return the
demographic questionnaire, which will
require 5 minutes (0.08 hours) to
complete for a total of 110 hours. Thus,
the total estimated burden is 839 hours.
FDA’s burden estimate is based on prior
experience with consumer surveys that
are similar to this proposed data
collection.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
No. of
respondents
Portion of study
Annual
frequency
per response
Total annual
responses
Hours per
response
Total hours
Pretest mailed questionnaire ...............................................
Pretest telephone interview .................................................
Main study mailed questionnaire .........................................
Main study telephone interview ...........................................
Demographic questionnaire .................................................
91
9
1,538
522
1,380
1
1
1
1
1
91
9
1,538
522
1,380
0.42
0.42
0.33
0.33
0.08
38
4
513
174
110
Total ..............................................................................
........................
........................
........................
........................
839
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
II. References
The following reference has been
placed on display in the Division of
Dockets Management (see ADDRESSES)
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday.
1. Fein, Sara B., Judith Labiner-Wolfe,
Katherine Shealy, et al., ‘‘Infant Feeding
Practices Study II: Study Methods,’’
Pediatrics 2008; 122(suppl 2): S28–S35.
Dated: February 22, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–4459 Filed 2–28–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
jlentini on DSKJ8SOYB1PROD with NOTICES
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 USC,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
VerDate Mar<15>2010
18:42 Feb 28, 2011
Jkt 223001
Name of Committee: National Institute on
Drug Abuse Initial Review Group; Training
and Career Development Subcommittee.
Date: March 9–10, 2011.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz-Carlton Hotel at Pentagon City,
1250 South Hayes Street, Arlington, VA
22202.
Contact Person: Eliane Lazar-Wesley,
Ph.D., Health Scientist Administrator, Office
of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 4245, MSC
9550, 6001 Executive Blvd., Bethesda, MD
20892–9550, 301–451–4530, el6r@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA–
K Conflicts.
Date: March 9, 2011.
Time: 5 p.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz-Carlton Hotel at Pentagon City,
1250 South Hayes Street, Arlington, VA
22202.
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 4238, MSC
9550, 6001 Executive Blvd., Bethesda, MD
20892–9550, 301–402–6626,
gml45a@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Pharmacological Development of Treatment
Agents and Formulations or Tobacco
Dependence.
Date: March 18, 2011.
Time: 1 p.m. to 5 p.m.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Jose F. Ruiz, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, Room 4228, MSC 9550,
6001 Executive Blvd., Bethesda, MD 20892–
9550, (301) 451–3086, ruizjf@nida.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; High
Throughput Screening for Nicotinic Receptor
Subunits.
Date: March 24, 2011.
Time: 2:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 4238, MSC
9550, 6001 Executive Blvd., Bethesda, MD
20892–9550, 301–402–6626,
gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Training in Computational Neuroscience
(T90/R90).
Date: March 30, 2011.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Minna Liang, Ph.D.,
Scientific Review Officer, Grants Review
Branch, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH, Room
4226, MSC 9550, 6001 Executive Blvd.,
E:\FR\FM\01MRN1.SGM
01MRN1
Federal Register / Vol. 76, No. 40 / Tuesday, March 1, 2011 / Notices
Bethesda, MD 20892–9550, 301–435–1432,
liangm@nida.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Training in Neuroimaging (T90) (RFA DA11–
006).
Date: March 31, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Scott A Chen, PhD,
Scientific Review Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 4234, MSC
9550, 6001 Executive Blvd., Bethesda, MD
20892–9550, 301–443–9511,
chensc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: February 23, 2011.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–4544 Filed 2–28–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
jlentini on DSKJ8SOYB1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
MAPGen and MAPGenKB studies.
Date: March 16, 2011.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: YingYing Li-Smerin, MD,
PhD, Scientific Review Officer, Office of
Scientific Review/DERA, National Heart,
Lung, and Blood Institute, 6701 Rockledge
VerDate Mar<15>2010
18:42 Feb 28, 2011
Jkt 223001
Drive, Room 7184, Bethesda, MD 20892–
7924, 301–435–0277, lismerin@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Cardiovascular Integrity and Remodeling.
Date: March 17, 2011.
Time: 9 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Giuseppe Pintucci, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7192,
Bethesda, MD 20892, 301–435–0287,
Pintuccig@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Informatics Tools and Services to Support
Data Sharing and Distribution for
Cardiovascular, Lung, and Blood
Researchers.
Date: March 18, 2011.
Time: 2 p.m. to 4:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Youngsuk Oh, PhD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7182, Bethesda, MD 20892–7924, 301–435–
0277, yoh@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Strategy for Finding Cases of Moderate-toSevere COPD.
Date: March 22, 2011.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Youngsuk Oh, PhD,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7182, Bethesda, MD 20892–7924, 301–435–
0277, yoh@mail.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Phenotype finder in data resources review
meeting.
Date: March 23, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance, Washington, DC Hotel,
999 Ninth Street, NW., Washington, DC
20001–4427.
Contact Person: Keith A. Mintzer, PhD,
Scientific Review Officer, Review Branch/
DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7186,
Bethesda, MD 20892–7924, 301–435–0280,
mintzerk@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
11253
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: February 23, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–4548 Filed 2–28–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Diabetes Biomarkers
Ancillary Studies.
Date: March 28, 2011.
Time: 10 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call).
Contact Person: Paul A. Rushing, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes Of Health,
Room 747, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Ancillary
Studies.
Date: March 30, 2011.
Time: 12 p.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892. (Telephone
Conference Call).
Contact Person: Barbara A Woynarowska,
PhD, Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes Of
Health, Room 754, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
402–7172, woynarowskab@niddk.nih.gov.
E:\FR\FM\01MRN1.SGM
01MRN1
]]>Agencies
[Federal Register Volume 76, Number 40 (Tuesday, March 1, 2011)]
[Notices]
[Pages 11252-11253]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-4544]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
USC, as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Initial
Review Group; Training and Career Development Subcommittee.
Date: March 9-10, 2011.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes
Street, Arlington, VA 22202.
Contact Person: Eliane Lazar-Wesley, Ph.D., Health Scientist
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 4245, MSC 9550, 6001 Executive Blvd.,
Bethesda, MD 20892-9550, 301-451-4530, el6r@nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA-K Conflicts.
Date: March 9, 2011.
Time: 5 p.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes
Street, Arlington, VA 22202.
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, NIH, DHHS, Room 4238, MSC 9550, 6001 Executive Blvd.,
Bethesda, MD 20892-9550, 301-402-6626, gml45a@nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Pharmacological Development of Treatment Agents and
Formulations or Tobacco Dependence.
Date: March 18, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Jose F. Ruiz, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse, NIH,
Room 4228, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550,
(301) 451-3086, ruizjf@nida.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; High Throughput Screening for Nicotinic Receptor
Subunits.
Date: March 24, 2011.
Time: 2:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, NIH, DHHS, Room 4238, MSC 9550, 6001 Executive Blvd.,
Bethesda, MD 20892-9550, 301-402-6626, gm145a@nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Training in Computational Neuroscience (T90/R90).
Date: March 30, 2011.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Minna Liang, Ph.D., Scientific Review Officer,
Grants Review Branch, Office of Extramural Affairs, National
Institute on Drug Abuse, NIH, Room 4226, MSC 9550, 6001 Executive
Blvd.,
[[Page 11253]]
Bethesda, MD 20892-9550, 301-435-1432, liangm@nida.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Training in Neuroimaging (T90) (RFA DA11-006).
Date: March 31, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Scott A Chen, PhD, Scientific Review
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 4234, MSC 9550, 6001 Executive Blvd.,
Bethesda, MD 20892-9550, 301-443-9511, chensc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: February 23, 2011.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-4544 Filed 2-28-11; 8:45 am]
BILLING CODE 4140-01-P
